Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
9989 Stock Chart & Stats
HK$5.19
HK$0.02(0.54%)
At close: 4:00 PM EST
HK$5.19
HK$0.02(0.54%)
Day’s Range― - ―
52-Week RangeHK$3.93 - HK$7.26
Previous CloseN/A
Volume172.00K
Average Volume (3M)1.16M
Market Cap
HK$17.20B
Enterprise ValueHK$14.91B
Total Cash (Recent Filing)HK$2.83B
Total Debt (Recent Filing)HK$2.11B
Price to Earnings (P/E)19.6
Beta0.95
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.23%
Share Statistics
EPS (TTM)-0.17
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.53
Revenue Forecast (FY)HK$6.58B
Bulls Say, Bears Say
Bulls Say
Stronger Balance SheetMaterial deleveraging to a ~0.18 debt-to-equity position provides durable financial flexibility. Lower leverage reduces refinancing and interest risks, supports capex/R&D or CDMO capacity expansion, and helps withstand industry cyclicality, strengthening long-term solvency and strategic optionality.
Improved Cash GenerationA sustained shift to positive operating and free cash flow across 2024–2025 improves internal funding for operations, reduces reliance on external financing, and enables reinvestment in manufacturing or CDMO capacity. Consistent FCF enhances resilience and supports longer term strategic execution.
Specialized API & CDMO Business MixA focus on heparin APIs plus finished formulations and CDMO services creates a specialized, multi-stream business model with high technical barriers. This vertical and service mix supports recurring contracts, regulatory moats, and diversified revenue sources that underpin durable competitive position in anticoagulant supply chains.
Bears Say
Profitability Volatility & Margin CompressionMaterial swings in net margin indicate persistent margin pressure or cost/revenue mix issues. Continued compression makes earnings less predictable, limits ability to fund growth from profits, and raises the risk that temporary improvements may reverse, undermining sustainable shareholder returns.
Uneven Revenue GrowthVolatile top-line trends reduce visibility for capacity planning and weaken bargaining power with customers. Modest growth around low single digits suggests slower secular expansion or customer concentration risks, constraining durable earnings growth and scale benefits over the medium term.
Low Shareholder Returns (ROE)A low ROE despite a stronger balance sheet signals inefficient capital deployment or margin constraints. Persistently weak returns limit the company's ability to fund dividends, attract capital, or justify reinvestment, creating a structural obstacle to sustained shareholder value creation.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$3.93 and its highest was HK$7.26 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$17.20B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Apr 30, 2026 which is in 24 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.169 earnings per share for the quarter, the consensus estimate of -HK$0.169 by HK$0.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.272 which represents an annual dividend yield of 5.23%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of -HK$0.169 in its last earnings report, expectations of -HK$0.169. Following the earnings report the stock price went up 1.018%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.12%
12-Months-Change
Fundamentals
Return on Equity
3.43%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
―
CanSino Biologics, Inc. Class H
―
Options Prices
Currently, No data available
---